1. Inicio
  2. Publicaciones
  3. Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis

Edge-to-edge percutaneous mitral repair for functional ischaemic and non-ischaemic mitral regurgitation: a systematic review and meta-analysis

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Chiarito, Mauro
  • Pighi, Michele
  • Cannata, Francesco
  • Rubbio, Antonio Popolo
  • Munafo, Andrea
  • Cao, Davide
  • Roccasalva, Fausto
  • Pini, Daniela
  • Pagnotta, Paolo A.
  • Ettori, Federica
  • Petronio, Anna Sonia
  • Tamburino, Corrado
  • Reimers, Bernhard
  • Colombo, Antonio
  • Di Mario, Carlo
  • Grasso, Carmelo
  • Mehran, Roxana
  • Godino, Cosmo
  • Stefanini, Giulio G.

Grupos

Abstract

Aim Randomized controlled trials comparing the use of the MitraClip device in addition to guideline directed medical therapy (GDMT) to GDMT alone in patients with secondary mitral regurgitation (MR) have shown conflicting results. However, if these differences could be due to the underlying MR aetiology is still unknown. Therefore, we aimed to evaluate if the effects of percutaneous edge-to-edge repair with MitraClip implantation could differ in patients with ischaemic (I-MR) and non-ischaemic mitral regurgitation (NI-MR). Methods and results PubMed, Embase, BioMed Central, and the Cochrane Central Register of Controlled Trials were searched for all studies including patients with secondary MR treated with the MitraClip device. Data were pooled using a random-effects model. Primary endpoint was the composite of all-cause death and heart failure-related hospitalization. Secondary endpoints were the single components of the primary endpoint, New York Heart Association functional Classes Ill and IV, and mitral valve re-intervention. Seven studies enrolling 2501 patients were included. Patients with I-MR compared with patients with NI-MR had a similar risk of the primary endpoint (odds ratio: 1.17; 95% confidence interval: 0.93 to 1.46; I-2: 0%). The risk of all-cause death was increased in patients with I-MR (odds ratio: 1.31; 95% confidence interval: 1.07 to 1.62; I-2: 0%), while no differences were observed between the two groups in terms of the other secondary endpoints. Conclusions The risk of mortality after MitraClip implantation is lower in patients with NI-MR than in those with I-MR. No absolute differences in the risk of heart failure related hospitalization were observed between groups.

© 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Datos de la publicación

ISSN/ISSNe:
2055-5822, 2055-5822

Esc Heart Failure  WILEY PERIODICALS, INC

Tipo:
Article
Páginas:
3177-3187
Factor de Impacto:
0,797 SCImago ℠
Cuartil:
Q2 SCImago ℠

Citas Recibidas en Web of Science: 3

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Secondary mitral regurgitation; Heart failure; Percutaneous edge-to-edge repair; MitraClip

Campos de estudio

Proyectos asociados

MECANISMOS DE ENFERMEDAD EN LA MIOCARDIOPATIA ARRITMOGENICA, MEJORAS EN SU DIAGNOSTICO Y BUSQUEDA DE DIANAS TERAPEUTICAS.

Investigador Principal: ESTHER ZORIO GRIMA

PI14/01477 . INSTITUTO DE SALUD CARLOS III . 2015

INCORPORACIÓN GRUPOS CIBER. DR. DOLZ

Investigador Principal: LUIS VICENTE MARTÍNEZ DOLZ

CB16/11/00261 . INSTITUTO DE SALUD CARLOS III . 2017

ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, BASADO EN EVENTOS, QUE COMPARA LA EFICACIA Y SEGURIDAD DE RIVAROXABAN CON PLACEBO EN LA REDUCCIÓN DEL RIESGO DE MUERTE, INFARTO DE MIOCARDIO O ICTUS, EN PACIENTES CON INSUFICIENCIA CARDIACA Y ENFERMEDAD ARTERIAL CORONARIA SIGNIFICATIVA TRAS UN EPISODIO DE INSUFICIENCIA CARDIACA DESCOMPENSADA.

Investigador Principal: LUIS ALMENAR BONET

RIVAROXHFA3001/BAY59-7939/16302 . 2013

EVALUACIÓN, EN PACIENTES CON PROCESOS MÉDICOS, DE RIVAROXABAN FRENTE A PLACEBO EN LA REDUCCIÓN DEL RIESGO DE TROMBOEMBOLISMO VENOSO DESPUÉS DEL ALTA HOSPITALARIA. (MARINER).

Investigador Principal: JOSÉ ANTONIO TODOLÍ PARRA

RIVAROXDVT3002/BAY59-7939/17261

Ensayo clínico aleatorizado para evaluar el efecto de los betabloqueantes y los antiagregantes plaquetarios en pacientes con disección espontánea de la arteria coronaria.

Investigador Principal: JOSÉ LUIS DÍEZ GIL

BA-SCAD . 2021

ASSESSING THE EFFECT OF DAPAGLIFOZIN ON PLAQUE PROGRESSION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION DAPA-PLACA.

Investigador Principal: JORGE SANZ SÁNCHEZ

DAPA-PLACA . 2021

Uninterrupted direct-acting oral anticoagulation in patients undergoing transradial percutaneous coronary procedures. DOAC-NOSTOP.

Investigador Principal: JORGE SANZ SÁNCHEZ

DOAC-NOSTOP . 2021

Cita

Compartir